We are live on ! Find out more
PM

Prosight Management Portfolio holdings

AUM $580M
1-Year Est. Return 29.81%
This Fund
S&P 500
This Quarter Est. Return
+1.14%
1 Year Est. Return
+29.81%
3 Year Est. Return
+39.55%
5 Year Est. Return
-6.93%
10 Year Est. Return
–
AUM
$610M
AUM Growth
+$126M
Cap. Flow
+$157M
Cap. Flow %
25.76%
Top 10 Hldgs %
65.04%
Holding
54
New
16
Increased
19
Reduced
10
Closed
8

Top Buys

Rank Stock Value
1
BSX icon
Boston Scientific
BSX
+$46.8M
2
WGS icon
GeneDx Holdings
WGS
+$42.7M
3
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$20M
4
ALKS icon
Alkermes
ALKS
+$15.9M
5
PRCT icon
Procept Biorobotics
PRCT
+$15.9M

Top Sells

Rank Stock Value
1
ICLR icon
Icon
ICLR
+$20M
2
FOLD
Amicus Therapeutics
FOLD
+$16.4M
3
SEM
Select Medical
SEM
+$15.4M
4
ROIV icon
Roivant Sciences
ROIV
+$11.5M
5
AVTR icon
Avantor
AVTR
+$10.3M

Sector Composition

Rank Sector Weight
1 Healthcare 99.84%
2 Industrials 0.16%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NKTR icon
1
Nektar Therapeutics
NKTR
$2.48B
$52.9M 8.67%
735,000
+180,367
+33% +$10.3M
BSX icon
2
Boston Scientific
BSX
$67.9B
$49.9M 8.19%
795,547
+585,547
+279% +$46.8M
JANX icon
3
Janux Therapeutics
JANX
$1.1B
$49.3M 8.09%
3,550,000
+1,157,477
+48% +$15.9M
PRCT icon
4
Procept Biorobotics
PRCT
$1.19B
$48.6M 7.98%
1,945,000
+565,000
+41% +$15.9M
LKFT
5
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.89B
$46.5M 7.63%
1,550,000
+475,888
+44% +$15.8M
WGS icon
6
GeneDx Holdings
WGS
$2.57B
$33.6M 5.51%
523,463
+468,463
+852% +$42.7M
STTK icon
7
Shattuck Labs
STTK
$707M
$32.2M 5.28%
5,004,439
+2,622,937
+110% +$12.4M
ADCT icon
8
ADC Therapeutics
ADCT
$146M
$31.1M 5.1%
8,300,000
-177,338
-2% -$699K
KURA icon
9
Kura Oncology
KURA
$1.13B
$27.3M 4.48%
3,356,700
+827,100
+33% +$7.11M
ALNY icon
10
Alnylam Pharmaceuticals
ALNY
$31.7B
$25.1M 4.12%
76,000
+58,891
+344% +$20M
MGTX icon
11
MeiraGTx Holdings
MGTX
$1.33B
$22.8M 3.73%
2,629,971
-579,817
-18% -$4.4M
ALKS icon
12
Alkermes
ALKS
$7.95B
$18.2M 2.98%
+513,632
New +$15.9M
SNDX icon
13
Syndax Pharmaceuticals
SNDX
$1.74B
$18M 2.95%
770,000
+105,000
+16% +$2.28M
VEEV icon
14
Veeva Systems
VEEV
$44.8B
$15.2M 2.49%
86,480
-3,653
-4% -$718K
ZYME icon
15
Zymeworks
ZYME
$2.02B
$13.5M 2.21%
539,049
+8,656
+2% +$205K
CRNX icon
16
Crinetics Pharmaceuticals
CRNX
$9B
$12.7M 2.08%
350,000
+87,096
+33% +$3.89M
ABVX
17
Abivax
ABVX
$9.89B
$11.7M 1.92%
105,000
+88,000
+518% +$10.4M
CON
18
Concentra Group Holdings
CON
$4.37B
$10.8M 1.78%
505,822
-385,208
-43% -$8.57M
TERN
19
DELISTED
Terns Pharmaceuticals
TERN
$10.7M 1.75%
202,300
+107,300
+113% +$4.41M
PHR icon
20
Phreesia
PHR
$751M
$9.22M 1.51%
1,100,000
+122,848
+13% +$1.62M
OKUR
21
OnKure Therapeutics
OKUR
$153M
$8.92M 1.46%
2,154,381
+1,337,472
+164% +$4.13M
CRBP icon
22
Corbus Pharmaceuticals
CRBP
$211M
$6.55M 1.07%
697,108
+13,236
+2% +$111K
SDGR icon
23
Schrodinger
SDGR
$1.47B
$5.8M 0.95%
+510,578
New +$7.06M
EBS icon
24
Emergent Biosolutions
EBS
$303M
$5.3M 0.87%
+639,118
New +$6.62M
ROIV icon
25
Roivant Sciences
ROIV
$25.1B
$4.99M 0.82%
180,000
-447,162
-71% -$11.5M
1
2 3

Similar funds

SC
Stempoint Capital New York $581M AUM 373.68% 1-Year Est. Return
CCWM
Correct Capital Wealth Management Clayton, Missouri $580M AUM 16.45% 1-Year Est. Return
CMA
Cedar Mountain Advisors Lake Oswego, Oregon $581M AUM 18.16% 1-Year Est. Return
RIS
Retirement Income Solutions Ann Arbor, Michigan $581M AUM 19.42% 1-Year Est. Return
MFS
McNamara Financial Services Marshfield, Massachusetts $580M AUM 17.89% 1-Year Est. Return
GFI
Global Frontier Investments Charleston, South Carolina $581M AUM 8.55% 1-Year Est. Return
PWM
Praetorian Wealth Management Carmel, California $580M AUM 19.43% 1-Year Est. Return
CA
COFG Advisors Oak Brook, Illinois $579M AUM

Prosight Management's Q1 2026 Portfolio in Review

As of Q1 2026, Prosight Management held 54 positions worth $610M, up 26% from $484M the previous quarter. Its ten largest holdings account for 65% of the portfolio.

Prosight Management deployed $157M of net new capital in Q1 2026, opening 16 new positions and adding to 19 existing holdings. Its largest new stake was Alkermes: 513,632 shares worth $18.2M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Industrials.

On the sell side, the largest reduction was Roivant Sciences, an estimated $11.5M trimmed.

  • Prosight Management's largest Q1 2026 buy was Alkermes: 513,632 shares worth $18.2M.
  • Prosight Management added most to Boston Scientific in Q1 2026, an estimated $46.8M increase.
  • Prosight Management's biggest Q1 2026 reduction was Roivant Sciences, cutting an estimated $11.5M.
  • Prosight Management fully exited Icon in Q1 2026, selling an estimated $20M.
  • Prosight Management's ten largest holdings make up 65% of its $610M portfolio in Q1 2026.
  • Prosight Management opened 16 new positions and closed 8 in Q1 2026.
  • Prosight Management's portfolio value rose 26% quarter-over-quarter to $610M.

Based on Prosight Management's 13F filing for Q1 2026, filed 15 May 2026.